2. Signaling Pathways
  3. Immunology/Inflammation
  4. NOD-like Receptor (NLR)
  5. NLRP3 Isoform
  6. NLRP3 Inhibitor

NLRP3 Inhibitor

NLRP3 Inhibitors (73):

Cat. No. Product Name Effect Purity
  • HY-130252
    YQ128
    		Inhibitor 99.83%
    YQ128 is a potent and selective second-generation NLRP3 (NOD-like receptor P3) inflammasome inhibitor with an IC50 of 0.30 μM. YQ128 significantly and selectively suppresses the production of IL-1β, but not TNF-α, and it can cross the BBB to reach the CNS. YQ128 has anti-inflammatory activity. YQ128 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • HY-130494
    (±)11(12)-EET
    		Inhibitor 98.3%
    (±)11(12)-EET is a NLRP3 inflammasome inhibitor. (±)11(12)-EET can be used for the research of anti-inflammatory, angiogenic and cardioprotective.
  • HY-120007
    JC124
    		Inhibitor 99.17%
    JC124 is a specific NLRP3 inflammasome inhibitor. JC124 has anti-inflammatory and neuroprotective effects.
  • HY-122920
    Soyasaponin II
    		Inhibitor 99.81%
    Soyasaponin II is a saponin with antiviral activity. Soyasaponin II inhibits the replication of HSV-1, HCMV, influenza virus, and HIV-1. Soyasaponin II shows potent inhibition on HSV-1 replication. Soyasaponin II serves as a inhibitor for YB-1 phosphorylation and NLRP3 inflammasome priming and could protect mice against LPS/GalN induced acute liver failure.
  • HY-137245
    Emlenoflast
    		Inhibitor 98.19%
    Emlenoflast (MCC7840), a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. Emlenoflast can be used for the research of inflammatory diseases.
  • HY-W082785A
    L6H21
    		Inhibitor 99.46%
    L6H21, a Chalcone (HY-121054) derivative, is an orally active, potent and specific myeloid differentiation 2 (MD-2) inhibitor. L6H21 directly binds to MD-2 protein with a high affinity and low KD value of 33.3?μM, blocking the formation of the LPS-TLR4/MD-2 complex. L6H21 inhibits LPS-induced expression of TNF-α and IL-6 in RAW264.7 macrophages, with IC50 values of 6.58 and 8.59 μM, respectively. L6H21 can be used for alcoholic liver disease, metabolic disturbance and neuroinflammation research.
  • HY-101868
    INF39
    		Inhibitor 99.86%
    INF39 is an irreversible and noncytotoxic NLRP3 inhibitor.
  • HY-164304
    INF 195
    		Inhibitor 99.58%
    INF 195 is an NLRP3 inhibitor. INF 195 can inhibit NLRP3 driven macrophage pyroptosis and IL-1β release, with an EC50 value of 0.15 μM. INF 195 can reduce the infarct size of isolated mouse hearts at low doses, effectively preventing myocardial ischemia/reperfusion injury.
  • HY-137888A
    Oxidized ATP trisodium salt
    		Inhibitor ≥98.0%
    Oxidized ATP (oATP) trisodium salt is a broad-spectrum P2 receptor inhibitor. Oxidized ATP trisodium salt irreversibly antagonizes P2X7R activation. Oxidized ATP trisodium salt inhibits c-reactive protein (CRP)-induced NLRP3 inflammasome activation. Oxidized ATP trisodium salt can be used for research of atherosclerosis.
  • HY-155751
    HMGB1-IN-1
    		Inhibitor 99.37%
    HMGB1-IN-1 (compound 6) displays strong NO inhibitory effect in RAW264.7 cells with IC50 value of 15.9 ± 0.6 μM. HMGB1-IN-1 inhibit the HMGB1/NF-κB/NLRP3 pathway. HMGB1-IN-1 shows good anti-inflammatory activity and good anti-sepsis effects in kidney injury.
  • HY-163358
    SLC3037
    		Inhibitor 99.85%
    SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases.
  • HY-137245A
    Emlenoflast sodium
    		Inhibitor 98.76%
    Emlenoflast (MCC7840) sodium, a sulfonylurea, is a potent and selective inhibitor of NLRP3 inflammasome, with an IC50 of <100 nM. Emlenoflast sodium can be used for the research of inflammatory diseases.
  • HY-163159
    NP3-562
    		Inhibitor 98.16%
    NP3-562 is a potent, orally active, tricyclic NLRP3 Inhibitor, with an IC50 of 214 nM. NP3-562 (30 mg/kg, p.o.) inhibits IL-1β release in a mouse acute peritonitis model.
  • HY-153554
    NLRP3-IN-18
    		Inhibitor 98.06%
    NLRP3-IN-18 (compound 13) is a potent NLRP3 inhibitor with an IC50 value of ≤1.0 µM.
  • HY-162333
    BAL-0028
    		Inhibitor
    BAL-0028 is a reversible inhibitor of NLRP3 activation with an IC50 value of 25 nM. BAL-0028 binds closely to the NACHT domain of the NLRP3 with KD values of 104-123 nM. BAL-0028 can inhibit the secretion of IL-1β and has anti-inflammatory activity.
  • HY-156034A
    JT001 sodium
    		Inhibitor 98.10%
    JT001 (NLRP3-IN-19) sodium is a potent, specific and orally active inhibitor of NLRP3. JT001 sodium can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 sodium can be used for the research of nonalcoholic steatohepatitis and liver fibrosis.
  • HY-N3242
    Moronic acid
    		Inhibitor 98.6%
    Moronic Acid is a triterpenoid compound, which is an orally available anti-HIV agent with anti-inflammatory activity. Moronic Acid can inhibit viral replication, with an EC50 value of <1 μg/mL. Moronic Acid can be isolated from Brazilian propolis.
  • HY-153261
    NLRP3-IN-17
    		Inhibitor 99.23%
    NLRP3-IN-17 is a potent, selective and orally active NLRP3 inflammasome inhibitor with an IC50 value of 7 nM. NLRP3-IN-17 significantly inhibits NLRP3 dependent IL-1β secretion in mice and can be used for chronic inflammatory diseases research.
  • HY-148187
    NLRP3-IN-11
    		Inhibitor 98.79%
    NLRP3-IN-11 is a NLR family pyrin domain containing 3 (NLRP3) proteins inhibitor. NLRP3-IN-11 has biological activity for NLRP3 with an IC50 value of <0.3 μM. NLRP3-IN-11 can be used for the researh of inflammatory and degenerative diseases including NASH, atherosclerosis and other cardiovascular diseases, Alzheimer's disease, Parkinson's disease, diabetes, gout, and numerous other autoinflammatory diseases.
  • HY-W011082
    NLRP3-IN-2
    		Inhibitor 98.00%
    NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism.